KFBIO

The firm provides end-to-end digital pathology solutions, addressing the entire workflow from sample processing to diagnosis. Its business is structured around five main segments: digital pathology slide scanners, routine pathology equipment, a telepathology platform, pathology AI, and pathology diagnostic services. The product line includes high-throughput and fluorescence scanners capable of automatically processing up to 400 slides. These scanners digitize traditional glass slides into high-resolution images, a process that can take as little as 25-40 seconds per slide. This technology is compatible with both bright-field and fluorescence scanning. KFBIO also develops AI-powered analysis software, such as the K-analyzer, which assists pathologists by performing tasks like high-speed nucleus counting and detecting positive/negative cells, thereby reducing workload and improving diagnostic accuracy. The company's solutions support remote diagnosis through a platform that allows for real-time consultations and data sharing, even over low-speed networks.

KFBIO has achieved several key milestones, including receiving a CE Certificate for its high-precision slide scanner in 2014 and becoming a National Hi-tech Enterprise in 2016. In 2017, it established an AI R&D Center in Hangzhou and now operates five R&D centers across Ningbo, Hangzhou, Nanjing, Shanghai, and Tokyo. A significant achievement came in 2019 when KFBIO obtained the medical device registration certificate for its Cervical Cancer and TB AI Screening System. The company's financing history includes a Series A round in 2016, a Series B round in 2020 led by Intel Capital, and a Series C round in 2022 of over 100 million RMB. Over 2,000 hospitals are reported to use KFBIO's products.